Literature DB >> 23992569

Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression.

Wouter van den Bijllaardt1, Helen M Siers, Caroline Timmerman-Kok, Franciscus G Pessers, Gerard Natrop, Joep F van Baars, Nynke Nutma, Douwe van der Werf, Elizabeth H Gisolf.   

Abstract

BACKGROUND: Increasing numbers of travelers using immunosuppressive drugs visit hepatitis A endemic countries. Data on protection rates after hepatitis A vaccination in this group are scarce.
METHODS: In this retrospective study, records of subjects with hepatitis A serology taken after vaccination were searched for in travel clinic databases. Relation between immunosuppressive drug use, age, gender, and time between vaccination and serology was evaluated.
RESULTS: Seroprotection rates within 4 weeks after primary vaccination (50%) are lower than after 4 weeks (64%). After the complete series of two vaccinations seroprotection rates reach 95% although success depends on the immunosuppressive drug being used. Subjects under anti-TNF alpha treatment have significantly lower seroprotection rates than subjects using classical immunosuppressive drugs after the second vaccination. There is no influence of age or gender on seroprotection rates.
CONCLUSIONS: Last-minute vaccination in subjects using immunosuppressive medication is not reliable, only 60% of our subjects had a protective antibody level after a single vaccination. When serology was done within 4 weeks after a single vaccination, seroprotection rates were only 50%, after 4 weeks this number rose to 64%. When persons visit a travel clinic in time for a complete vaccination series, satisfactory seroprotection rates can be reached. Seroprotection rate depends on the drug being used, persons using anti-TNF alpha are less protected.
© 2013 International Society of Travel Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23992569     DOI: 10.1111/jtm.12050

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  3 in total

1.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09

Review 2.  Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.

Authors:  Giuseppe Murdaca; Giovanni Noberasco; Dario Olobardi; Claudio Lunardi; Matteo Maule; Lorenzo Delfino; Massimo Triggiani; Chiara Cardamone; Devis Benfaremo; Gianluca Moroncini; Angelo Vacca; Nicola Susca; Sebastiano Gangemi; Paola Quattrocchi; Laura Sticchi; Giancarlo Icardi; Andrea Orsi
Journal:  Vaccines (Basel)       Date:  2021-12-02

Review 3.  [Travel vaccinations in rheumatic diseases : Specific considerations in children and adults].

Authors:  T Welzel; A Wörner; U Heininger
Journal:  Z Rheumatol       Date:  2020-11       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.